Summary

Tamiflu (Oseltamivir Phosphate) Market – Scope of Report
TMR’s report on the global tamiflu (oseltamivir phosphate) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global tamiflu (oseltamivir phosphate) market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global tamiflu (oseltamivir phosphate) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the tamiflu (oseltamivir phosphate) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global tamiflu (oseltamivir phosphate) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global tamiflu (oseltamivir phosphate) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global tamiflu (oseltamivir phosphate) market.

The report delves into the competitive landscape of the global tamiflu (oseltamivir phosphate) market. Key players operating in the global tamiflu (oseltamivir phosphate) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global tamiflu (oseltamivir phosphate) market profiled in this report.

Key Questions Answered in Global tamiflu (oseltamivir phosphate) Market Report
• What is the sales/revenue generated by tamiflu (oseltamivir phosphate) across all regions during the forecast period?
• What are the opportunities in the global tamiflu (oseltamivir phosphate) market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Tamiflu (Oseltamivir Phosphate) Market – Research Objectives and Research Approach
The comprehensive report on the global tamiflu (oseltamivir phosphate) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global tamiflu (oseltamivir phosphate) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global tamiflu (oseltamivir phosphate) market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Tamiflu (Oseltamivir Phosphate) Market
4. Market Overview
    4.1. Introduction
        4.1.1. Drug Type Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, 2020-2034
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Influenza Flu Prevalence Globally
    5.2. Porter’s Five Forces Analysis
    5.3. Key Industry Events
    5.4. Regulatory Scenario
6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Drug Type, 2020-2034
        6.3.1. Branded
        6.3.2. Generic
    6.4. Market Attractiveness By Drug Type
7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Dosage
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Dosage, 2020-2034
        7.3.1. Capsule
        7.3.2. Suspension
    7.4. Market Attractiveness By Dosage
8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Indication
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By Indication, 2020-2034
        8.3.1. Influenza A
        8.3.2. Influenza B
        8.3.3. Others
    8.4. Market Attractiveness By Indication
9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast By Distribution Channel, 2020-2034
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
        9.3.4. Others
    9.4. Market Attractiveness By Distribution Channel
10. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Region
    10.1. Key Findings
    10.2. Market Value Forecast By Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Drug Type, 2020-2034
        11.2.1. Branded
        11.2.2. Generic
    11.3. Market Value Forecast By Dosage, 2020-2034
        11.3.1. Capsule
        11.3.2. Suspension
    11.4. Market Value Forecast By Indication, 2020-2034
        11.4.1. Influenza A
        11.4.2. Influenza B
        11.4.3. Others
    11.5. Market Value Forecast By Distribution Channel, 2020-2034
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
        11.5.4. Others
    11.6. Market Value Forecast By Country, 2020-2034
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Type
        11.7.2. By Dosage
        11.7.3. By Indication
        11.7.4. By Distribution Channel
        11.7.5. By Country
12. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Drug Type, 2020-2034
        12.2.1. Branded
        12.2.2. Generic
    12.3. Market Value Forecast By Dosage, 2020-2034
        12.3.1. Capsule
        12.3.2. Suspension
    12.4. Market Value Forecast By Indication, 2020-2034
        12.4.1. Influenza A
        12.4.2. Influenza B
        12.4.3. Others
    12.5. Market Value Forecast By Distribution Channel, 2020-2034
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
        12.5.4. Others
    12.6. Market Value Forecast By Country, 2020-2034
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Type
        12.7.2. By Dosage
        12.7.3. By Indication
        12.7.4. By Distribution Channel
        12.7.5. By Country
13. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Drug Type, 2020-2034
        13.2.1. Branded
        13.2.2. Generic
    13.3. Market Value Forecast By Dosage, 2020-2034
        13.3.1. Capsule
        13.3.2. Suspension
    13.4. Market Value Forecast By Indication, 2020-2034
        13.4.1. Influenza A
        13.4.2. Influenza B
        13.4.3. Others
    13.5. Market Value Forecast By Distribution Channel, 2020-2034
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
        13.5.4. Others
    13.6. Market Value Forecast By Country, 2020-2034
        13.6.1. China
        13.6.2. India
        13.6.3. Japan
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Type
        13.7.2. By Dosage
        13.7.3. By Indication
        13.7.4. By Distribution Channel
        13.7.5. By Country
14. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Drug Type, 2020-2034
        14.2.1. Branded
        14.2.2. Generic
    14.3. Market Value Forecast By Dosage, 2020-2034
        14.3.1. Capsule
        14.3.2. Suspension
    14.4. Market Value Forecast By Indication, 2020-2034
        14.4.1. Influenza A
        14.4.2. Influenza B
        14.4.3. Others
    14.5. Market Value Forecast By Distribution Channel, 2020-2034
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
        14.5.4. Others
    14.6. Market Value Forecast By Country, 2020-2034
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Type
        14.7.2. By Dosage
        14.7.3. By Indication
        14.7.4. By Distribution Channel
        14.7.5. By Country
15. Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast By Drug Type, 2020-2034
        15.2.1. Branded
        15.2.2. Generic
    15.3. Market Value Forecast By Dosage, 2020-2034
        15.3.1. Capsule
        15.3.2. Suspension
    15.4. Market Value Forecast By Indication, 2020-2034
        15.4.1. Influenza A
        15.4.2. Influenza B
        15.4.3. Others
    15.5. Market Value Forecast By Distribution Channel, 2020-2034
        15.5.1. Hospital Pharmacies
        15.5.2. Retail Pharmacies
        15.5.3. Online Pharmacies
        15.5.4. Others
    15.6. Market Value Forecast By Country, 2020-2034
        15.6.1. GCC
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Drug Type
        15.7.2. By Dosage
        15.7.3. By Indication
        15.7.4. By Distribution Channel
        15.7.5. By Country
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2022)
    16.3. Company Profiles
        16.3.1. F. Hoffmann-La Roche Ltd.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. NATCO Pharma Limited
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Teva Pharmaceutical Industries Ltd
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. LUPIN Limited
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Amneal pharmaceuticals LLC
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Zydus Cadila
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Sun Pharmaceutical Industries Ltd.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Alembic Pharmaceuticals Limited
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Mylan N.V.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Hetero Group
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview